IsoPlexis expands single-cell systems with conclusion of USD 20m in Series C financing.
M2 EQUITYBITES-January 13, 2020-IsoPlexis expands single-cell systems with conclusion of USD 20m in Series C financing
(C)2020 M2 COMMUNICATIONS http://www.m2.com
IsoPlexis has announced that it has secured an additional USD 20 million to its Series C financing, bringing the entire Series C round to USD 45 million, the company said.
The funding will continue to drive the global commercial expansion of its IsoLight single-cell proteomic analysis platform. The recent financing was led by Northpond Ventures, along with participation from existing investors.
The IsoLight single-cell system is used globally by leading biotech, pharma and academic medical centers to solve critical challenges in cell therapy, cancer immunology, and inflammatory disease.
In 2020, IsoPlexis will continue to expand its applications and release innovative products addressing high need research areas for its existing and future customer base, including products that address innate & myeloid function, tumor cell signaling, and other high need areas.
IsoPlexis is dedicated to accelerating the fight against cancer and a range of the world's toughest diseases with its correlative single-cell detection systems. By revealing unique immune biomarkers in small subsets of cells, the company is advancing immunotherapies and targeted therapies to a more highly precise and personalized stage.
((Comments on this story may be sent to email@example.com))